Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Analysts at FBR & Co issued their FY2019 earnings per share (EPS) estimates for shares of Supernus Pharmaceuticals in a note issued to investors on Monday. FBR & Co analyst D. Buck expects that the specialty pharmaceutical company will post earnings of $2.35 per share for the year. FBR & Co has a “Buy” rating and a $53.00 price objective on the stock. FBR & Co also issued estimates for Supernus Pharmaceuticals’ FY2020 earnings at $3.25 EPS.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%.
SUPN has been the subject of a number of other research reports. BidaskClub downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and set a $51.00 price target on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. Cowen and Company set a $50.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a research report on Monday. Janney Montgomery Scott assumed coverage on Supernus Pharmaceuticals in a research report on Friday, July 14th. They set a “neutral” rating and a $47.00 price target for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $47.00 price target (up from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $48.38.
Supernus Pharmaceuticals (SUPN) traded down 3.98% during midday trading on Tuesday, reaching $39.85. 412,304 shares of the company traded hands. Supernus Pharmaceuticals has a 1-year low of $17.25 and a 1-year high of $50.04. The stock has a market capitalization of $2.02 billion, a P/E ratio of 20.11 and a beta of 1.30. The firm has a 50-day moving average of $42.49 and a 200-day moving average of $40.01.
In related news, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 8th. The stock was sold at an average price of $47.60, for a total transaction of $2,380,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 3,709 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total value of $167,758.07. Following the transaction, the vice president now owns 17,500 shares of the company’s stock, valued at $791,525. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 153,709 shares of company stock valued at $7,223,108. 6.70% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in SUPN. UBS Asset Management Americas Inc. raised its position in Supernus Pharmaceuticals by 77.4% during the first quarter. UBS Asset Management Americas Inc. now owns 17,737 shares of the specialty pharmaceutical company’s stock valued at $555,000 after acquiring an additional 7,737 shares in the last quarter. Karp Capital Management Corp purchased a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at approximately $247,000. OppenheimerFunds Inc. purchased a new stake in shares of Supernus Pharmaceuticals in the first quarter valued at approximately $205,000. Principal Financial Group Inc. increased its position in shares of Supernus Pharmaceuticals by 4.6% in the first quarter. Principal Financial Group Inc. now owns 409,242 shares of the specialty pharmaceutical company’s stock valued at $12,809,000 after buying an additional 17,864 shares in the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Supernus Pharmaceuticals by 16.5% in the first quarter. Wellington Management Group LLP now owns 225,905 shares of the specialty pharmaceutical company’s stock valued at $7,070,000 after buying an additional 31,945 shares in the last quarter. Institutional investors own 94.71% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.